25-GI-141-RBI-PMC (RYZ801-101): Phase 1/1b Single Arm, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)

Grants and Contracts Details

StatusActive
Effective start/end date9/17/25 → 9/17/27

Funding

  • RayzeBio Incorporated: $2.00